^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Multiple Myeloma
    Drug:pomalidomide (TNFα inhibitor, IL-6 inhibitor, NK cell stimulant, IL-10 stimulant, IL-1β inhibitor) +
    Empliciti (elotuzumab) (CS-1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    EMPLICITI is a SLAMF7-directed immunostimulatory antibody indicated in...combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
    Secondary therapy:
    dexamethasone
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    The NCCN panel has included the combination of pomalidomide/dexamethasone/elotuzumab as an option for patients who have received at least two prior therapies...
    Secondary therapy:
    dexamethasone